Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in the treatment of systemic lupus erythematosus (SLE) did not achieve a statistically significant difference between daxdilimab and a placebo in reaching the primary endpoint. The primary measure was the proportion of patients achieving a British Isles Lupus […]
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology company will pay $116.5 per share in cash, which is a premium of around 19.7% to Horizon Therapeutics’ closing stock price of $97.29 per share on 9 December 2022. Horizon […]
Glenmark Pharmaceuticals said that it has bagged final approval for Sodium Phenylbutyrate Tablets USP, 500 mg by the US Food and Drug Administration (FDA). The approved product is a generic version of Buphenyl Tablets (sodium phenylbutyrate), 500 mg, of Horizon Therapeutics and is indicated for the treatment of urea cycle disorders. According to Glenmark Pharmaceuticals, […]
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline and grow its rare disease medicine portfolio. Viela Bio is focused on developing and commercializing therapies for a wide variety […]